Verve Therapeutics Inc (NASDAQ:VERV) currently has a daily average trading volume of 3.09M but it saw 2800997 shares traded in last market. With a market cap of 377.08M USD, the company’s current market price of $4.23 came falling about -8.24 while comparing to the previous closing price of $4.61. In past 52 weeks, the stock remained buoying in the range of price level as high as $9.31 and as low as $2.86.
Canaccord Genuity issued its recommendations for the stock as it initiated the price target for the stock is $29.
Over the week, VERV’s stock price is moving -1.86% down while it is -19.43% when we observe its performance for the past one month. Year-to-date it is -25.00% down and over the past year, the stock is showing a downside performance of -29.26%.
The company is expected to be releasing its next quarterly report in June, for which analysts forecasted an EPS of -0.67 while estimate for next year EPS is -2.4. In next quarter, company is expected to be making quarterly sales of $3.23M as analysts are expecting the sales for current fiscal year at $39.46M and seeing the company making $17.03M in sales next year. Moreover, analysts are in estimates of $3.37M for current-quarter revenue.
Currently, Verve Therapeutics Inc’s total number of outstanding shares is 88.80M with 5.19% of that held by the insiders while 94.70% of its common stock has been owned by the institutions. Company’s return on investment (ROI) stands at -34.05% and return on equity (ROE) at -34.26%. Stock’s beta reads 1.70. Stock has a price to book (P/B) ratio of 0.79 while price to sale or P/S ratio amounts to 6.33. Its return on asset (ROA) is -26.89% on average.
